Gepotidacin - GSK
Alternative Names: Blujepa; Gepotidacin mesilate; Gepotidacin mesylate hydrate; GSK 2140944; GSK-2140944ELatest Information Update: 02 Sep 2026
At a glance
- Originator GSK
- Class Acenaphthenes; Anti-infectives; Antibacterials; Aza compounds; Ketones; Piperidines; Pyridines; Pyrones; Small molecules; Urinary anti-infective agents
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gonorrhoea; Urinary tract infections
- Discontinued Respiratory tract infections; Skin and soft tissue infections
Most Recent Events
- 02 Sep 2026 Chemical structure information updated
- 23 Jul 2026 GSK initiates a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT07645235)
- 12 Jun 2026 GlaxoSmithKline plans a phase I Pharmacokinetics trial for Urinary tract infections (In volunteers) in June 2026 (PO) (NCT07645235)